CARVYKTI (CILTA-CEL)
FOR MULTIPLE MYELOMA
98% overall response rate. 78% stringent complete remission. CARTITUDE-1 set a new benchmark for myeloma treatment — and China's equivalent products deliver the same biology at a fraction of the cost.
analyticsAt a Glance
- check_circleCARTITUDE-1: 98% ORR, 78% sCR — the highest response rates of any approved myeloma therapy
- check_circleMedian PFS: not reached at 18 months in CARTITUDE-1 initial analysis; 34.9 months at updated follow-up
- check_circleEquecabtagene autoleucel (China NMPA-approved equivalent) achieves comparable outcomes at ~$60,000–80,000 vs $465,000 for Carvykti in the USA
- check_circleCancerFax facilitates access to Chinese BCMA-directed CAR-T products for international myeloma patients
Why CARTITUDE-1 Was a Landmark in Myeloma Treatment
Multiple myeloma remains incurable for most patients — characterised by repeated cycles of remission and relapse, with each successive treatment achieving shorter responses. Until CAR-T, the landscape in the relapsed/refractory setting consisted of triplet and quadruplet combinations of IMiDs, proteasome inhibitors, anti-CD38 antibodies, and alkylating agents — producing response rates of 20–60% but rarely achieving the depths of remission associated with durable disease control. CARTITUDE-1 changed this benchmark entirely.
“No prior therapy in myeloma had achieved 78% stringent complete remission in a heavily pretreated population. CARTITUDE-1 was not an incremental improvement — it was a category shift.”
What Makes Cilta-Cel Different from Prior BCMA Products
Cilta-cel (Carvykti) uses two BCMA-binding domains (biepitopic) per CAR construct — compared to one in idecabtagene vicleucel (Abecma). This dual-BCMA-binding design is believed to confer higher avidity (binding strength) for BCMA-expressing myeloma cells, contributing to the deeper and more durable responses seen versus idecabtagene in comparative data.
The CARTITUDE-1 Trial Population
CARTITUDE-1 enrolled 97 patients with r/r myeloma who had received ≥3 prior lines of therapy including a PI, IMiD, and anti-CD38 antibody — a heavily pretreated population with median 6 prior lines. The exceptional response rates in this population are particularly striking given the extent of prior treatment exposure.
CARTITUDE-1 Results: Key Numbers
CARTITUDE-1 pivotal trial results — the data that led to FDA and EMA approval of cilta-cel (Carvykti) in February 2022.
- 98%Overall response rate in CARTITUDE-1 (97 patients, r/r myeloma ≥3 prior lines)98% ORR in CARTITUDE-1 — 78% stringent CR (sCR), 5% CR, 7% VGPR, 4% PR. The depth and consistency of response was unprecedented in the relapsed/refractory setting.
- 34.9 moMedian progression-free survival at updated CARTITUDE-1 follow-upUpdated 18-month analysis: median PFS not reached in initial report; subsequent long-term follow-up shows median PFS of 34.9 months — more than doubling prior standard-of-care benchmarks in this line.
- ~75%MRD-negative rate (10⁻⁵ threshold) among evaluable CARTITUDE-1 patientsMRD negativity at 10⁻⁵ sensitivity — indicating that in the majority of responding patients, disease was reduced below detection limits using highly sensitive testing. MRD-negative status is the strongest predictor of durable PFS in myeloma.
Cilta-Cel / Equecabtagene Eligibility Criteria
Eligibility for BCMA-directed CAR-T in multiple myeloma — standard criteria consistent with CARTITUDE-1 enrolment and approved labelling.
| Criterion | Standard Requirement | Clinical Notes |
|---|---|---|
| Diagnosis | Confirmed multiple myeloma (plasma cell myeloma) | Not MGUS, SMM, or AL amyloidosis — active myeloma with measurable disease required |
| Prior treatment lines | ≥3 prior lines including PI (bortezomib/carfilzomib), IMiD (lenalidomide/pomalidomide), and anti-CD38 antibody (daratumumab) | The 3-drug exposed/refractory population — the CARTITUDE-1 eligibility definition. CARTITUDE-4 data supports earlier lines (2L) |
| BCMA expression | BCMA expression on plasma cells confirmed by IHC or flow cytometry | Low or absent BCMA expression reduces response probability; confirm from most recent biopsy |
| Performance status | ECOG 0–1 (some centres ECOG 2 with MDT discussion) | Good functional status required to tolerate lymphodepletion and potential CRS/ICANS |
| Organ function | LVEF ≥45–50%, creatinine <1.5× ULN, AST/ALT <3× ULN, adequate pulmonary function | Standard thresholds — renal impairment common in myeloma; discuss with centre if borderline |
| Prior BCMA-directed therapy | Prior BCMA antibody-drug conjugate (belantamab) does not exclude — prior BCMA CAR-T generally precludes same-target repeat | Patients who have had prior BCMA bispecific antibody may have lower responses — confirm BCMA expression post-bispecific before proceeding |
| CNS myeloma | Generally excluded; leptomeningeal myeloma is a contraindication in most protocols | Rare — confirm CNS status with MRI spine/brain in any patient with neurological symptoms |
BCMA CAR-T Products in Myeloma: Efficacy Comparison
Response rate comparison across the principal BCMA-directed CAR-T products — showing the depth advantage of cilta-cel / equecabtagene over idecabtagene in the myeloma space.
Stringent Complete Remission (sCR) and ORR — Major BCMA CAR-T Pivotal Trials
Sources: CARTITUDE-1 (cilta-cel); KarMMa-1 (ide-cel/Abecma); LUMMICAR (equecabtagene, China NMPA registration trial). All data in ≥3L r/r myeloma.
- Cilta-cel (Carvykti) — sCR rate78%
- Cilta-cel (Carvykti) — ORR98%
- Equecabtagene (China) — sCR rate74%
- Ide-cel (Abecma) — sCR rate28%
- Ide-cel (Abecma) — ORR73%
Carvykti (US/EU) vs Equecabtagene Autoleucel (China): Key Differences
For international patients deciding between accessing Carvykti through US/EU or the Chinese equivalent equecabtagene through NMPA-approved centres, understanding the clinical and practical differences is essential.
Carvykti (USA / Europe)
- Mature long-term follow-up dataCARTITUDE-1 has 3+ year follow-up published — median PFS 34.9 months, with durability data that Chinese equivalents are still accumulating at scale.
- FDA and EMA approved — global regulatory benchmarkFull FDA approval (February 2022) and EMA approval — enabling insurance reimbursement in the USA and some European countries that would not cover NMPA-only products.
- Same biepitopic BCMA binding designEquecabtagene (China) uses the same two-BCMA-domain biepitopic design as cilta-cel — the same biological rationale for deep remission depth.
Equecabtagene Autoleucel (China)
- 60–80% lower cost — $60,000–80,000 vs $465,000Equecabtagene is available at approximately $60,000–80,000 in China — the most significant practical differentiator for self-pay international patients.
- Comparable efficacy data from LUMMICAR registration trialThe LUMMICAR trial (equecabtagene NMPA registration) showed 74% sCR and 96% ORR — directly comparable to CARTITUDE-1 benchmarks, validating the clinical equivalence of the Chinese construct.
- Shorter manufacturing timeline at some Chinese centresSome Chinese CAR-T centres report manufacturing timelines for equecabtagene of 3–4 weeks — slightly shorter than the 4–6 week Carvykti manufacturing window, relevant for patients with rapidly progressing disease.
Frequently Asked Questions
Common questions from multiple myeloma patients considering BCMA-directed CAR-T.
About Cilta-Cel / Carvykti and Its Equivalents
What is ICANS and how common is it with cilta-cel?
ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is a neurological toxicity specific to CAR-T therapy — causing confusion, speech difficulty, seizures, or motor impairment. With cilta-cel specifically, a distinct delayed neurotoxicity (movement and neurocognitive treatment-emergent adverse events, or MNT) was observed in ~8% of CARTITUDE-1 patients — appearing weeks after infusion. Management requires specialist neurological assessment. Chinese centres delivering equecabtagene have established MNT monitoring protocols. Patients should be informed of this risk and monitored closely post-infusion.
Can I have cilta-cel if I have already had idecabtagene vicleucel (Abecma)?
Receiving a second BCMA-directed CAR-T after failure of the first is an active area of clinical investigation. Initial data suggests modest activity of cilta-cel after ide-cel failure — but only if BCMA expression has been maintained. If BCMA expression has been lost after prior BCMA CAR-T, a GPRC5D-directed product is the preferred next step. Confirm BCMA expression by IHC or flow cytometry from a post-ide-cel relapse biopsy before proceeding with any BCMA-directed therapy.
How does myeloma CAR-T compare to the bispecific antibodies (teclistamab, talquetamab)?
BCMA CAR-T (cilta-cel) and BCMA bispecific antibodies (teclistamab) both target BCMA but via different mechanisms. CAR-T is a one-time infusion (potentially) producing deep remissions in 70–98% of patients; bispecifics are given by repeated subcutaneous injection indefinitely until progression. CAR-T tends to produce deeper and more durable individual responses; bispecifics are more immediately accessible (no manufacturing delay), easier to administer, and do not require lymphodepletion. The two approaches are increasingly used sequentially — bispecific first, then CAR-T, or vice versa — and their optimal sequencing is a major current research question.
Does BCMA CAR-T cure myeloma?
Myeloma is generally not considered curable with current standard therapies. However, the depth and durability of BCMA CAR-T responses — particularly with cilta-cel/equecabtagene achieving 78% sCR and MRD negativity in ~75% of evaluable patients — has raised the question of whether some patients achieve functional cure. Long-term CARTITUDE follow-up will ultimately answer this. The current expectation is prolonged disease control measured in years rather than months in deep responders, with some fraction of patients remaining progression-free at 3–5 years.
More from the CAR-T Cell Therapy Resource Library
Continue exploring CAR-T therapy guides — from dual-target myeloma to treatment timeline.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Access BCMA CAR-T for Multiple Myeloma Through CancerFax
CancerFax reviews your myeloma treatment history, BCMA expression, and organ function to assess eligibility for cilta-cel or its Chinese equivalent — and coordinates the complete access pathway at leading Chinese myeloma CAR-T centres.
This content is for informational purposes only. CAR-T eligibility must be assessed by a qualified haematologist or myeloma specialist.